Healthcare
Telesis Bio, Inc.(TBIO)
Live Price
Offline$0.001
+0.00% today
1Y Change
-99.00%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- +0.3%
- EPS Growth
- +3.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telesis Bio, Inc. (TBIO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.0% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +0.3%, EPS growth of +3.6%, a dividend yield of 0.0%. What stands out right now is revenue +0.3%, EPS +3.6%, free cash flow +15.1% with operating margin -169.2% and ROIC -72.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines TBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.3% vs +7.6% peer median
Operating Margin
Below sector median
-169.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.3% and EPS at +3.6%, with operating margin around -169.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -98.0% | -98.0% | -99.8% |
2026 Mar 27, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Nov 5, 2025 | โ | +0.0% | +75.0% | +75.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBIO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TBIO Max Drawdown
-99.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TBIO and SPY.
Company Overview
Telesis Bio, Inc.
Other OTC
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
- Leadership
- Eric Esser
- IPO Date
- Jun 18, 2021
- Employees
- 39
- Street Address
- 29 Hartwell Ave
- Mailing
- Lexington, MA, 92121-2993
- Region
- Lexington, MA, US
- Reporting Currency
- USD
- Investor Line
- 16179457361
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.1
- Price/Book
- 0.1
Growth
- Revenue
- +0.3%
- EPS
- +3.6%
- Free Cash Flow
- +15.1%
Profitability
- Gross Margin
- 61.6%
- Operating Margin
- -169.2%
- Net Margin
- -173.5%
- ROE
- -125.4%
- ROIC
- -72.7%
Balance Sheet
- Debt/Equity
- 1.16
- Current Ratio
- 3.71
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.